Skip to main content

Kura Oncology, Inc 10-Q for FY2026 Q3

Kura Oncology, Inc. (KURA)

10-Q 2026-11-10 For: 2026-09-30
View Original
Added on November 10, 2026

About this 10-Q

Kura Oncology, Inc filed this 10-Q on November 10, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Kura Oncology reported $28.8 million in KOMZIFTI net product revenue for the nine months ended September 30, 2026. Cash, cash equivalents and short-term investments totaled $492.1 million as of September 30, 2026. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$22.84M
up 10.1% from $20.75M a year earlier
Net loss
$70.22M
compared with a net loss of $74.12M a year earlier
Diluted EPS
-$0.78
compared with -$0.85 a year earlier